PALO ALTO, Calif., Feb. 24 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.,
a start-up biotechnology company developing antiviral therapies, announced
that it has raised $7.1 million in a Series A financing co-led by InterWest
Partners and Vivo Ventures. The two firms were instrumental in the formation
of the company and recruitment of its team and are represented on the board of
directors by general partners Nina Kjellson and Dr. Edgar Engelman,
respectively. The funding will advance the company's lead program targeted
against NS4B, a specific region in the hepatitis C virus (HCV) protein, as
well as progress lead identification for other proprietary targets.
Eiger is led by President and Chief Executive Officer David Cory, RPh,
MBA, whose background spans over 20 years in large pharma, biotechnology, and
specialty pharma with an established track record of commercial success,
financial transactions, business development, and management experience. "We
believe that disrupting the normal function of NS4B and NS5A proteins will
lead to uniquely effective hepatitis C treatments," said David Cory, President
and CEO of Eiger. "Our mission is to advance these novel small molecules into
the clinic rapidly for the benefit of patients."
Eiger was founded on research conducted by Stanford professor Jeffrey
Glenn, MD, PhD, whose recent research focuses on specific regions of HCV
proteins NS4B and NS5A required for viral replication. "The unmet medical need
in HCV treatment is significant," said Dr. Glenn. "Developing small molecule
drugs and drug combinations against new HCV targets could change the HCV
treatment paradigm and combat the emergence of drug resistance to new HCV
polymerase and protease inhibitors." Dr. Glenn is Associate Professor of
Medicine, Gastroenterology & Hepatology, Stanford University and Director of
the Center for Hepatitis and Liver Tissue Engineering; he wi
'/>"/>
SOURCE Eiger BioPharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors2.
Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss3.
Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter4.
XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter5.
XTL Biopharmaceuticals Announces Receipt of NASDAQ Notice of Delisting6.
XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives7.
Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference8.
Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.9.
XTL Biopharmaceuticals Implements Restructuring Plan10.
Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights11.
Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients